Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-search-preview· OpenAIHugging Face LMArena Search Arena 24K

residual disease was independent prognostic factor in ovarian cancer

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Perplexitysonar-reasoning’s answer.
  1. User

    residual disease was independent prognostic factor in ovarian cancer

  2. Assistant

    Residual disease, defined as the amount of tumor remaining after cytoreductive surgery, is a significant independent prognostic factor in ovarian cancer. Studies consistently demonstrate that the extent of residual disease directly impacts patient survival outcomes.

    A meta-analysis encompassing 50 studies found that median progression-free survival and overall survival decreased progressively with increasing residual disease. Compared to no residual disease, the hazard ratios for disease progression were 1.75 for residual disease >0–1 cm and 2.14 for residual disease >1 cm. Similarly, the hazard ratios for reduced survival were 1.75 for residual disease >0–1 cm and 2.32 for residual disease >1 cm. These findings underscore that higher amounts of residual disease are associated with poorer survival outcomes[1].

    Another study focusing on patients with FIGO stage IIIC and IV epithelial ovarian cancer reported that macroscopic residual disease after interval debulking surgery was an independent prognostic factor for survival. Notably, leaving residual tumor less than one centimeter was associated with a survival benefit of five months compared to leaving residual tumor more than one centimeter. This benefit was observed after interval debulking surgery but not after primary debulking surgery, indicating that the prognostic value of residual tumor may depend on the clinical setting[2].

    These findings highlight the critical importance of achieving complete cytoreduction during surgery to improve survival outcomes in ovarian cancer patients.

  3. User

    From the initial approval of cyclophosphamide by the U.S. Food and Drug Administration (FDA) for the treatment of ovarian cancer in 1959 to the introduction of cisplatin in 1978, the treatment landscape of advanced ovarian cancer has been completely changed.

  4. Assistant

    The treatment landscape for advanced ovarian cancer underwent significant transformations between the late 1950s and the late 1970s, marked by the introduction of key chemotherapeutic agents.

    Cyclophosphamide, an alkylating agent, was approved by the U.S. Food and Drug Administration (FDA) in 1959. It became a cornerstone in the treatment of various cancers, including ovarian cancer, due to its ability to interfere with DNA replication, thereby inhibiting cancer cell proliferation[1].

    The late 1970s saw the advent of cisplatin, a platinum-based chemotherapeutic agent. FDA approval for cisplatin was granted on December 19, 1978, specifically for the treatment of metastatic ovarian tumors[2]. Cisplatin's mechanism involves binding to DNA and forming cross-links, which disrupt DNA replication and transcription, leading to cancer cell death. Its introduction significantly improved remission rates and overall survival in ovarian cancer patients.

    The combination of cisplatin with other agents, such as paclitaxel, further enhanced treatment efficacy. Clinical trials demonstrated that the cisplatin-paclitaxel regimen was more effective than previous combinations, leading to its adoption as a standard first-line therapy for advanced ovarian cancer[3].

    These developments between 1959 and 1978 marked a pivotal era in ovarian cancer treatment, transitioning from alkylating agents like cyclophosphamide to platinum-based therapies, thereby significantly improving patient outcomes.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.